Flutemetamol (18F)
Clinical data | |
---|---|
Trade names | Vizamyl |
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
Pregnancy category |
|
Routes of administration | Intravenous |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
PubChem CID | |
ChemSpider | |
UNII | |
ChEBI | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C14H1118FN2OS |
Molar mass | 273.316 g/mol |
3D model (JSmol) | |
| |
|
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Flutemetamol (18F) (trade name Vizamyl, by GE Healthcare) is a PET scanning radiopharmaceutical containing the radionuclide fluorine-18, used as a diagnostic tool for Alzheimer's disease.[1]
Mechanism of action
After the substance is given intravenously, it accumulates in beta amyloid plaques in the patient's brain, which thus become visible via positron emission tomography (PET).[1]
References
Categories:
- Pages with script errors
- CS1 maint: Unrecognized language
- Template:drugs.com link with non-standard subpage
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Infobox drug articles with non-default infobox title
- Chemical articles without CAS registry number
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles containing unverified chemical infoboxes
- Drug
- Alzheimer's disease
- Radiocontrast agents
- Organofluorides